• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form F-6 filed by NuCana plc

    4/24/25 5:25:08 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NCNA alert in real time by email
    F-6 1 e664423_f6-nucana.htm

     

    As filed with the Securities and Exchange Commission on April 24, 2025

    Registration No. 333  - 

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    _________________________________

     

    FORM F-6

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933 FOR AMERICAN DEPOSITARY SHARES EVIDENCED BY

    AMERICAN DEPOSITARY RECEIPTS

    ____________

     

    NUCANA PLC

    (Exact name of issuer of deposited securities as specified in its charter)

    ____________

     

    N/A

    (Translation of issuer’s name into English)

    ____________

     

    England and Wales

    (Jurisdiction of incorporation or organization of issuer)

    _________________________________

     

    CITIBANK, N.A.

    (Exact name of depositary as specified in its charter)

    ____________

     

    388 Greenwich Street

    New York, New York 10013

    (877) 248-4237

    (Address, including zip code, and telephone number, including area code, of depositary’s principal executive offices)

    ____________

     

    Corporation Service Company

    251 Little Falls Drive, Wilmington, DE 19808

    United States

    (302) 421-6100

    (Address, including zip code, and telephone number, including area code, of agent for service)

    _________________________________

     

    Copies to:

     

    William C. Hicks, Esq.

    John T. Rudy, Esq.

    Allyson Wilkinson, Esq.

    Mintz, Levin, Cohn, Ferris, Glovsky

    and Popeo, P.C.

    One Financial Center

    Boston, Massachusetts 02111

    (617) 542-6000

     

    Herman H. Raspé, Esq.

    Jean-Claude Lanza, Esq.

    Patterson Belknap Webb & Tyler LLP
    1133 Avenue of the Americas
    New York, New York 10036
    (212) 336-2000

    _________________________________

     

    It is proposed that this filing become effective under Rule 466:  ☐ immediately upon filing.
       
       ☐ on (Date) at (Time).
       
    If a separate registration statement has been filed to register the deposited shares, check the following box: ☒

      _________________________________

     

    CALCULATION OF REGISTRATION FEE

     

    Title of Each Class of
    Securities to be Registered
    Amount to be
    Registered

    Proposed Maximum

    Aggregate Price Per Unit*

    Proposed Maximum

    Aggregate Offering Price**

    Amount of

    Registration Fee

    American Depositary Shares (the “ADS(s))”, each ADS representing the right to receive twenty-five (25) ordinary shares of NuCana plc (the “Company”) 2,000,000,000 ADSs $5.00 $100,000,000 $15,310.00
     

    *     Each unit represents 100 ADSs.

    **   Estimated solely for the purpose of calculating the registration fee. Pursuant to Rule 457(k), such estimate is computed on the basis of the maximum aggregate fees or charges to be imposed in connection with the issuance of ADSs.

     

    The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until this Registration Statement shall become effective on such date as the United States Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

      

     

     

     

     

    This Registration Statement may be executed in any number of counterparts, each of which shall be deemed an original, and all of such counterparts together shall constitute one and the same instrument.

     

     

    ii

     

     

    PART I

     

    INFORMATION REQUIRED IN PROSPECTUS

     

    Cross Reference Sheet

     

    Item 1.DESCRIPTION OF SECURITIES TO BE REGISTERED

     

    Item Number and Caption

     

    Location in Form of American

    Depositary Receipt (“Receipt”)
    Filed Herewith as Prospectus

         
    1. Name of Depositary and address of its principal executive office   Face of Receipt - Introductory Article.
           
    2. Title of Receipts and identity of deposited securities   Face of Receipt - Top Center.
             
      Terms of Deposit:    
             
      (i) The amount of deposited securities represented by one American Depositary Share ("ADSs")   Face of Receipt - Upper right corner.
             
      (ii) The procedure for voting, if any, the deposited securities   Reverse of Receipt - Paragraphs (17)
    and (18).
             
      (iii) The collection and distribution of dividends   Reverse of Receipt - Paragraph (15).
             
      (iv) The transmission of notices, reports and proxy soliciting material   Face of Receipt - Paragraph (14);
    Reverse of Receipt - Paragraph (18).
             
      (v) The sale or exercise of rights  

    Reverse of Receipt - Paragraphs (15)

    and (17).

             
      (vi) The deposit or sale of securities resulting from dividends, splits or plans of reorganization  

    Face of Receipt - Paragraphs (3) and (6);

    Reverse of Receipt - Paragraphs (15) and (17).

             
      (vii) Amendment, extension or termination of the deposit agreement   Reverse of Receipt - Paragraphs (23) and (24) (no provision for extensions).
             
      (viii) Rights of holders of Receipts to inspect the transfer books of the Depositary and the list of holders of ADSs   Face of Receipt - Paragraph (14).
             

     

     

    I-1

     

     

     

     

    Item Number and Caption

     

    Location in Form of American

    Depositary Receipt (“Receipt”)

    Filed Herewith as Prospectus

             

      (ix) Restrictions upon the right to deposit or withdraw the underlying securities   Face of Receipt - Paragraphs (2), (3), (4), (6), (7), (9) and (10).
             
      (x) Limitation upon the liability of the Depositary  

    Face of Receipt - Paragraph (8);

    Reverse of Receipt - Paragraphs (20) and (21).

             
    3.     Fees and charges which may be imposed directly or indirectly on holders of ADSs   Face of Receipt - Paragraph (11).
             
    Item 2.  AVAILABLE INFORMATION   Face of Receipt - Paragraph (14).

     

    The Company is subject to the periodic reporting requirements of the United States Securities Exchange Act of 1934, as amended, and, accordingly, files certain reports with, and submits certain reports to, the United States Securities and Exchange Commission (the “Commission”). These reports can be retrieved from the Commission’s internet website (www.sec.gov), and can be inspected and copied at the public reference facilities maintained by the Commission at 100 F Street, N.E., Washington D.C. 20549.

      

    I-2

     

     

     

    PROSPECTUS

     

    The Prospectus consists of the proposed form of American Depositary Receipt included as Exhibit A to the Form of Amended and Restated Deposit Agreement filed as Exhibit (a)(i) to this Registration Statement on Form F-6 and is incorporated herein by reference.

      

     

    I-3

     

     

    PART II

     

    INFORMATION NOT REQUIRED IN PROSPECTUS

     

    Item 3.EXHIBITS

     

    (a)(i) Form of Amended and Restated Deposit Agreement, by and among NuCana plc (the “Company”), Citibank, N.A., as depositary (the “Depositary”), and all Holders and Beneficial Owners of American Depositary Shares issued thereunder (“Deposit Agreement”). ___ Filed herewith as Exhibit (a)(i).

     

    (ii) Amendment No. 1 to Deposit Agreement, dated as of April 16, 2024, by and among the Company, the Depositary, and all Holders and Beneficial Owners of American Depositary Shares issued thereunder. ___ Filed herewith as Exhibit (a)(ii).

     

    (iii) Deposit Agreement, dated as of October 2, 2017, by and among the Company, the Depositary, and all Holders and Beneficial Owners of American Depositary Shares issued thereunder. ___ Previously filed as Exhibit (a)(ii) to the Post-Effective Amendment No. 1 to the Registration Statement on Form F-6, Reg. No. 333-220392, filed on March 27, 2024, and incorporated herein by reference.

     

    (b)(i) At-the-Market Program Letter Agreement, dated as of April 6, 2020, by and between the Company and the Depositary. ___ Previously filed as Exhibit (b)(i) to the Post-Effective Amendment No. 1 to the Registration Statement on Form F-6, Reg. No. 333-220392, filed on March 27, 2024, and incorporated herein by reference.

     

    (ii) Restricted ADS Letter Agreement, dated as of July 31, 2018, by and between the Company and the Depositary. ___ Previously filed as Exhibit (b)(ii) to the Post-Effective Amendment No. 1 to the Registration Statement on Form F-6, Reg. No. 333-220392, filed on March 27, 2024, and incorporated herein by reference.

     

    (c)Every material contract relating to the deposited securities between the Depositary and the issuer of the deposited securities in effect at any time within the last three years. ___ None.

     

    (d)Opinion of counsel for the Depositary as to the legality of the securities to be registered. ___ Filed herewith as Exhibit (d).

     

    (e)Certificate under Rule 466. ___ None.

     

    (f)Powers of Attorney for certain officers and directors and the authorized representative of the Company. ___ Set forth on the signature pages hereto.

      

    II-1

     

     

    Item  4.UNDERTAKINGS

     

    (a)The Depositary undertakes to make available at the principal office of the Depositary in the United States, for inspection by holders of ADSs, any reports and communications received from the issuer of the deposited securities which are both (1) received by the Depositary as the holder of the deposited securities, and (2) made generally available to the holders of the underlying securities by the issuer.

     

    (b)If the amount of fees charged is not disclosed in the prospectus, the Depositary undertakes to prepare a separate document stating the amount of any fee charged and describing the service for which it is charged and to deliver promptly a copy of such fee schedule without charge to anyone upon request. The Depositary undertakes to notify each registered holder of an ADS thirty (30) days before any change in the fee schedule.

      

    II-2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, Citibank, N.A., acting solely on behalf of the legal entity to be created by the Amended and Restated Deposit Agreement, by and among NuCana plc, Citibank, N.A., as depositary, and all Holders and Beneficial Owners from time to time of American Depositary Shares to be issued thereunder, certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Registration Statement on Form F-6 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on the 24th day of April, 2025.

      

     

    Legal entity created by the Amended and Restated Deposit Agreement under which the American Depositary Shares registered hereunder are to be issued, each American Depositary Share representing the right to receive twenty-five (25) ordinary shares of NuCana plc.

     

    CITIBANK, N.A., solely in its capacity as Depositary 

         
      By: /s/ Joseph Connor
        Name: Joseph Connor
        Title: Attorney-in-Fact

     

     

    II-3

     

      

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, NuCana plc certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Registration Statement on Form F-6 to be signed on its behalf by the undersigned thereunto duly authorized, in Edinburgh, United Kingdom, on April 24, 2025.

      

     

    NUCANA PLC

         
      By: /s/ Hugh S. Griffith
        Name: Hugh S. Griffith
        Title: Chief Executive Officer

     

    II-4

     

     

    POWERS OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Hugh S. Griffith to act as his/her true and lawful attorney-in-fact and agent, with full power of substitution, for him/her and in his/her name, place and stead, in any and all such capacities, to sign any and all amendments, including post-effective amendments, and supplements to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the United States Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as s/he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his/her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form F-6 has been signed by the following persons in the following capacities on April 24, 2025.

      

    Signature   Title
         

    /s/ Hugh S. Griffith                       

    Hugh S. Griffith 

     

    Chief Executive Officer (Principal Executive Officer) and Director

         

    /s/ Ian Webster                              

    Ian Webster 

     

    Director of Finance (Principal Financial and Accounting Officer)

         

    /s/ Andrew Kay                             

    Andrew Kay 

     

     

    Chairman

         

    /s/ Cyrille Leperlier                       

    Cyrille Leperlier 

     

     

    Director

         

    /s/ Martin Mellish                          

    Martin Mellish

     

     

    Director

         

    /s/ Elliott Levy                               

    Elliott Levy

     

     

    Director

      

    II-5

     

     

    SIGNATURE OF AUTHORIZED REPRESENTATIVE OF THE REGISTRANT

     

    Under the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of America, has signed this Registration Statement on Form F-6 in Spring Branch, Texas, on April 23, 2025.

     

     

    NUCANA, INC.

         
      By: /s/ Jeffrey D. Bloss
      Name: Jeffrey D. Bloss, M.D.
      Title:

    Chief Medical Officer

     

    II-6

     

     

    Index to Exhibits

     

    Exhibit Document

    Sequentially

    Numbered Page

         
    (a)(i) Form of Amended and Restated Deposit Agreement  
         
    (a)(ii) Amendment No. 1 to Deposit Agreement  
         
    (d) Opinion of counsel to the Depositary  
         
         
         
         

     

     

    Get the next $NCNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NCNA

    DatePrice TargetRatingAnalyst
    8/30/2024Outperform → Mkt Perform
    William Blair
    3/3/2022Outperform → Market Perform
    Cowen & Co.
    11/24/2021$10.00 → $9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $NCNA
    Leadership Updates

    Live Leadership Updates

    See more
    • NuCana Appoints Elliott M. Levy, M.D. to its Board of Directors

      EDINBURGH, United Kingdom, Nov. 01, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer announced the appointment of Elliott M. Levy, M.D. to its Board of Directors. Dr. Levy brings over 20 years of experience at global pharmaceutical companies, including Amgen and Bristol-Myers Squibb, and has a strong track record of leading clinical strategy and development efforts for numerous programs at all stages of development. "We are thrilled to welcome Dr. Levy to our Board of Directors," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "He is a recognized

      11/1/21 4:01:00 PM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NuCana Appoints Jeffrey D. Bloss, M.D. as Chief Medical Officer

      EDINBURGH, United Kingdom, Aug. 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Jeffrey D. Bloss, M.D. as Chief Medical Officer. Dr. Bloss will be based in NuCana's US offices located outside Boston, MA. "We are delighted to welcome Jeff to the executive team at NuCana," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Jeff brings over two decades of experience leading clinical development and medical affairs at several biotechnology and pharmaceutical companies. His achievements include leading the development, approval and

      8/10/21 8:00:00 AM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NCNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • NuCana downgraded by William Blair

      William Blair downgraded NuCana from Outperform to Mkt Perform

      8/30/24 7:44:58 AM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NuCana downgraded by Cowen & Co.

      Cowen & Co. downgraded NuCana from Outperform to Market Perform

      3/3/22 6:12:40 AM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on NuCana with a new price target

      HC Wainwright & Co. reiterated coverage of NuCana with a rating of Buy and set a new price target of $9.00 from $10.00 previously

      11/24/21 6:13:12 AM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NCNA
    SEC Filings

    See more
    • SEC Form 6-K filed by NuCana plc

      6-K - NuCana plc (0001709626) (Filer)

      6/2/25 4:36:34 PM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B4 filed by NuCana plc

      424B4 - NuCana plc (0001709626) (Filer)

      5/7/25 7:32:35 AM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by NuCana plc

      EFFECT - NuCana plc (0001709626) (Filer)

      5/6/25 12:15:12 AM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NCNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NuCana Reports First Quarter 2025 Financial Results and Provides Business Update

      Initiation of Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data in 2026 Additional Data from the Ongoing Phase 1b/2 Study of NUC-3373 in Combination with Pembrolizumab Remain on track for 2025 Anticipated Cash Runway Extended into Q4 2026 to Support Key Value-Driving Milestones and Complete the Expansion Study of NUC-7738 EDINBURGH, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced financial results for the first quarter ended March 31, 2025 and provided an update on its clinical development prog

      6/2/25 4:01:00 PM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NuCana Prices $7 Million Registered Direct Offering

      EDINBURGH, United Kingdom, May 06, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), a clinical-stage biopharmaceutical company that focuses on significantly improving treatment outcomes for patients with cancer, announced that it has priced a registered direct offering consisting of 10,845,985 American Depository Shares, or ADSs, (or pre-funded warrants in lieu thereof) with each ADS (or pre-funded warrant) accompanied by (i) a Series A warrant to purchase one (1) ADS at an initial exercise price of $0.8068 per share and (ii) a Series B Warrant to purchase one (1) ADS at an initial exercise price of $1.61 per share. The combined public offering price of each ADS together with the accompa

      5/6/25 8:30:00 AM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

      Remains on Track to Initiate an Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma in 2025 Data from the Expansion Study to Support Interaction with FDA and Define Regulatory Strategy for NUC-7738 Data from the Ongoing Phase 1b/2 Study of NUC-3373 in Combination with Pembrolizumab Anticipated Cash Runway Extended into Q3 2025 EDINBURGH, United Kingdom, March 20, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced financial results for the fourth quarter and year ended December 31, 2024 and provided an update on its clinical development program with its two lead anti-cancer medicines. "Throughout 2024, we shared mul

      3/20/25 4:01:49 PM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NCNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by NuCana plc

      SC 13G/A - NuCana plc (0001709626) (Subject)

      10/4/24 10:14:46 AM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by NuCana plc (Amendment)

      SC 13D/A - NuCana plc (0001709626) (Subject)

      2/27/24 4:29:36 PM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by NuCana plc (Amendment)

      SC 13G/A - NuCana plc (0001709626) (Subject)

      2/14/24 4:26:01 PM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care